JP2007501271A - インシュリンを含有する液体エアロゾル配合物及びエアロゾル生成装置及びエアロゾル化インシュリンを生成するための方法 - Google Patents
インシュリンを含有する液体エアロゾル配合物及びエアロゾル生成装置及びエアロゾル化インシュリンを生成するための方法 Download PDFInfo
- Publication number
- JP2007501271A JP2007501271A JP2006532550A JP2006532550A JP2007501271A JP 2007501271 A JP2007501271 A JP 2007501271A JP 2006532550 A JP2006532550 A JP 2006532550A JP 2006532550 A JP2006532550 A JP 2006532550A JP 2007501271 A JP2007501271 A JP 2007501271A
- Authority
- JP
- Japan
- Prior art keywords
- aerosol
- insulin
- liquid
- formulation
- generating device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 330
- 239000000443 aerosol Substances 0.000 title claims abstract description 210
- 108090001061 Insulin Proteins 0.000 title claims abstract description 165
- 102000004877 Insulin Human genes 0.000 title claims abstract description 165
- 229940125396 insulin Drugs 0.000 title claims abstract description 163
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 238000009472 formulation Methods 0.000 title claims abstract description 98
- 239000008263 liquid aerosol Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims description 25
- 239000007788 liquid Substances 0.000 claims abstract description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000002245 particle Substances 0.000 claims abstract description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000009834 vaporization Methods 0.000 claims abstract description 7
- 230000008016 vaporization Effects 0.000 claims abstract description 7
- 230000015556 catabolic process Effects 0.000 claims abstract description 6
- 238000006731 degradation reaction Methods 0.000 claims abstract description 6
- 239000003380 propellant Substances 0.000 claims abstract description 6
- 239000012530 fluid Substances 0.000 claims description 41
- 239000003570 air Substances 0.000 claims description 40
- 238000010438 heat treatment Methods 0.000 claims description 30
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 14
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 13
- 239000012080 ambient air Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 6
- 239000012669 liquid formulation Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 12
- 238000012387 aerosolization Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 101001011741 Bos taurus Insulin Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 108010005991 Pork Regular Insulin Proteins 0.000 description 3
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000004026 insulin derivative Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000011819 refractory material Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000008275 solid aerosol Substances 0.000 description 2
- 238000013097 stability assessment Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000010963 304 stainless steel Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229910000589 SAE 304 stainless steel Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940084769 humulin r Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910001233 yttria-stabilized zirconia Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/008—Electronic counters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
- A61M15/025—Bubble jet droplet ejection devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/007—Syringe-type or piston-type sprayers or atomisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
- A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
- A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8237—Charging means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
【選択図】 図1
Description
図1は加熱された毛管路を有するエアロゾル生成器を示す。
Claims (50)
- インシュリン、及びキャリアの気化時に熱劣化からインシュリンを保護する少なくとも一つの高揮発性キャリアを含み、かつ噴射薬を含まない、エアロゾル化されたインシュリンからなる気化エアロゾルを形成するために適応された液体エアロゾル配合物。
- キャリアがエタノールであり、液体配合物が少なくとも50℃の温度である請求項1に記載の液体エアロゾル配合物。
- 第二成分がヒトインシュリンである請求項1に記載の液体エアロゾル配合物。
- 5重量%以下のヒトインシュリンを含む請求項3に記載の液体エアロゾル配合物。
- キャリアが10〜90容量%のエタノール及び90〜10容量%の水を含む請求項1に記載の液体エアロゾル配合物。
- インシュリンがキャリアに溶解される請求項1に記載の液体エアロゾル配合物。
- キャリアがエタノールであり、インシュリンがヒトインシュリンである請求項1に記載の液体エアロゾル配合物。
- 加熱時に蒸気を形成し、蒸気が周囲空気と混合される時に本質的にインシュリンからなるエアロゾル粒子からなるエアロゾルを生成するように配合された請求項1に記載の液体エアロゾル配合物。
- エアロゾル粒子が実質的に乾燥した固体粒子である請求項8に記載の液体エアロゾル配合物。
- 本質的にキャリア及びインシュリンからなる請求項1に記載の液体エアロゾル配合物。
- 蒸気に連行されるエアロゾル粒子を含有する噴射薬不含エアロゾルであって、エアロゾル粒子の実質的に全てが本質的にインシュリンからなり、蒸気が本質的に気化された液体キャリアからなる噴射薬不含エアロゾル。
- エアロゾルが0.01〜1μm又は1〜3μmの質量メジアン空気力学的粒径を有する請求項11に記載のエアロゾル。
- キャリアがエタノールと水の混合物である請求項11に記載のエアロゾル。
- 蒸気に連行されるインシュリンのエアロゾル粒子を含有するエアロゾルであって、エアロゾル粒子が本質的にインシュリンからなり、蒸気が噴射薬を含まず、エアロゾルが0.01〜1μm又は1〜3μmの質量メジアン空気力学的粒径を有するエアロゾル。
- 下記のものを含むエアロゾル生成装置:
高揮発性キャリア及びインシュリンを含む液体エアロゾル配合物の液体源;
液体源と流体連通する流路;及び
流路の加熱部分において液体エアロゾル配合物を加熱して蒸気を生成し、それを空気と混合してエアロゾルを生成するように配置された加熱器。 - キャリアがエタノールである請求項15に記載のエアロゾル生成装置。
- インシュリンがヒトインシュリンである請求項15に記載のエアロゾル生成装置。
- キャリアがエタノールと水の混合物である請求項17に記載のエアロゾル生成装置。
- 少なくとも20容量%の水を含む請求項17に記載のエアロゾル生成装置。
- インシュリンがキャリアに溶解される請求項15に記載のエアロゾル生成装置。
- 液体エアロゾル配合物が噴射薬を含まない請求項15に記載のエアロゾル生成装置。
- エアロゾルが本質的にインシュリンからなるエアロゾル粒子を含む請求項15に記載のエアロゾル生成装置。
- 加熱器が液体エアロゾル配合物を約100〜150℃に加熱するように操作可能である請求項15に記載のエアロゾル生成装置。
- エアロゾル粒子が本質的に実質的に乾燥した固体粒子からなる請求項15に記載のエアロゾル生成装置。
- 下記のものをさらに含む請求項15に記載のエアロゾル生成装置:
電力源;及び
流路において液体エアロゾル配合物を気化するのに有効な温度範囲で加熱器を維持するように電力を電力源から加熱器へ送出するように操作可能な制御器。 - 液体源と流路の間に配置された少なくとも一つの弁をさらに含む請求項25に記載のエアロゾル生成装置であって、制御器が弁を作動して流路を開閉し、液体源から流路への液体エアロゾル配合物の流れを制御するように操作可能であるエアロゾル生成装置。
- エアロゾルがエアロゾル生成装置の使用者によって吸入されるマウスピース;
圧力センサ;
空気がマウスピースに供給される空気路;及び
空気路を開閉する弁
をさらに含む請求項25に記載のエアロゾル生成装置であって、制御器が使用者がマウスピースで吸入して空気をマウスピース中に供給させるときに圧力センサがマウスピースにおける圧力低下を検出した後の予め決められた時間内に弁を作動するように操作可能であるエアロゾル生成装置。 - 流路が予め決められた容積を有する計量チャンバーを含み、エアロゾル生成装置が流路の加熱部分中へ予め決められた容量に等しい液体エアロゾル配合物の量を送出するように操作可能な放出部材を含む請求項15に記載のエアロゾル生成装置。
- ハンドヘルドの吸入器である請求項15に記載のエアロゾル生成装置。
- 液体源がエアロゾル生成装置に除去可能に取り付けられている請求項15に記載のエアロゾル生成装置。
- 下記のものを含むエアロゾル生成装置:
キャリア及びインシュリンを含む液体エアロゾル配合物の液体源;
液体源と流体連通する流路;及び
流路の加熱部分における液体エアロゾル配合物を加熱して蒸気を生成し、それを空気と混合してエアロゾルを生成するように配置された加熱器。 - 下記工程を含むエアロゾルを生成する方法:
(a)高揮発性キャリア及びインシュリンを含む液体エアロゾル配合物を流路に供給する;
(b)流路の加熱部分における液体エアロゾル配合物を加熱して蒸気を生成する;及び
(c)蒸気を空気と混合してエアロゾル化されたインシュリン粒子を生成する。 - キャリアがエタノールを含む請求項32に記載の方法。
- キャリアが水をさらに含む請求項32に記載の方法。
- インシュリンがヒトインシュリンである請求項34に記載の方法。
- キャリアがエタノール及び少なくとも10容量%の水を含む請求項32に記載の方法。
- インシュリンがキャリアに溶解される請求項32に記載の方法。
- 液体エアロゾル配合物が噴射薬を含まない請求項32に記載の方法。
- エアロゾルが本質的にインシュリンからなるエアロゾル粒子を含む請求項32に記載の方法。
- エアロゾル粒子が1μm未満の質量メジアン空気力学的粒径を有する請求項32に記載の方法。
- エアロゾル粒子が本質的に実質的に乾燥した固体粒子からなる請求項32に記載の方法。
- エアロゾルのエアロゾル粒子が3ミクロン未満の質量メジアン空気力学的粒径を有する請求項32に記載の方法。
- 流路が毛管サイズの円形流路であり、エアロゾル粒子が毛管路の内径より少なくとも4倍小さい質量メジアン空気力学的粒径を有する請求項32に記載の方法。
- 下記工程をさらに含む請求項32に記載の方法:
液体エアロゾル配合物の予め決められた容量を流路の加熱部分中に供給する;及び
液体エアロゾル配合物の予め決められた容量を加熱して蒸気を生成する。 - マウスピースを含むエアロゾル生成装置を使用して(a)〜(c)が実施される請求項32に記載の方法であって、下記工程をさらに含む方法:
マウスピースで吸入する使用者によって起こされるエアロゾル生成装置のマウスピースにおける圧力低下を検出する;
圧力低下を検出した後、液体エアロゾル配合物の予め決められた容量を流路の加熱部分中に供給する;及び
マウスピースを通してエアロゾルを使用者に送出する。 - エアロゾルを連続的に生成することを含む請求項32に記載の方法。
- 下記工程をさらに含む請求項32に記載の方法:
エアロゾル生成装置に取り付けられた第一流体送出集成体を使用して(a)〜(c)を実施する;
エアロゾル生成装置から第一流体送出集成体を除去する;
第二流体送出集成体をエアロゾル生成装置に取り付ける;及び
第二流体送出集成体を使用して(a)〜(c)を繰り返す。 - 第一流体送出集成体が第一液体エアロゾル配合物を供給し、第二流体送出集成体が第一液体エアロゾル配合物とは異なる第二液体エアロゾル配合物を供給する請求項47に記載の方法。
- 第一質量メジアン空気力学的粒径を有するエアロゾル粒子を含む第一エアロゾルを第一流体送出集成体で生成し、第一質量メジアン空気力学的粒径とは異なる第二質量メジアン空気力学的粒径を有するエアロゾル粒子を含む第二エアロゾルを第二流体送出集成体で生成することを含む請求項47に記載の方法。
- 下記工程を含むエアロゾルを生成する方法:
(a)インシュリンを含む液体エアロゾル配合物を流路に供給する;
(b)流路の加熱部分において液体エアロゾル配合物を加熱して蒸気を生成する;及び
(c)蒸気を空気と混合してエアロゾル化されたインシュリン粒子を生成する。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46826703P | 2003-05-07 | 2003-05-07 | |
US60/468,267 | 2003-05-07 | ||
US10/829,945 US7683029B2 (en) | 2003-05-07 | 2004-04-23 | Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin |
US10/829,945 | 2004-04-23 | ||
PCT/US2004/013758 WO2004100872A2 (en) | 2003-05-07 | 2004-05-05 | Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007501271A true JP2007501271A (ja) | 2007-01-25 |
JP5054381B2 JP5054381B2 (ja) | 2012-10-24 |
Family
ID=33423716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006532550A Expired - Lifetime JP5054381B2 (ja) | 2003-05-07 | 2004-05-05 | インシュリンを含有する液体エアロゾル配合物及びエアロゾル生成装置及びエアロゾル化インシュリンを生成するための方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7683029B2 (ja) |
EP (1) | EP1626746B1 (ja) |
JP (1) | JP5054381B2 (ja) |
AU (1) | AU2004238235B2 (ja) |
CA (1) | CA2524816C (ja) |
WO (1) | WO2004100872A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018011932A (ja) * | 2016-07-18 | 2018-01-25 | アウトスタンディング ヘルスケア カンパニー リミテッド | ハンドヘルド噴霧器 |
KR20180118701A (ko) * | 2016-03-24 | 2018-10-31 | 니코벤처스 홀딩스 리미티드 | 증기 제공 디바이스 |
US11123501B2 (en) | 2016-03-24 | 2021-09-21 | Nicoventures Holdings Limited | Electronic vapor provision system |
US11213638B2 (en) | 2016-03-24 | 2022-01-04 | Nicoventures Trading Limited | Vapor provision system |
US11241043B2 (en) | 2016-03-24 | 2022-02-08 | Nicoventures Trading Limited | Vapor provision apparatus |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
AU2003297087B2 (en) * | 2003-02-04 | 2009-06-11 | Philip Morris Products S.A. | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
WO2005037949A2 (en) * | 2003-10-07 | 2005-04-28 | Chrysalis Technologies Incorporated | Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine |
US20060102175A1 (en) * | 2004-11-18 | 2006-05-18 | Nelson Stephen G | Inhaler |
US7186958B1 (en) * | 2005-09-01 | 2007-03-06 | Zhao Wei, Llc | Inhaler |
US8442390B2 (en) * | 2007-08-29 | 2013-05-14 | Philip Morris Usa Inc. | Pulsed aerosol generation |
CA2709071C (en) | 2007-12-14 | 2016-11-15 | Labogroup S.A.S. | Delivering aerosolizable food products |
US8118023B2 (en) * | 2008-01-09 | 2012-02-21 | Short Michael J | CPAP system and method of use |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
US8650937B2 (en) | 2008-09-19 | 2014-02-18 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
AT507187B1 (de) * | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
US9250106B2 (en) | 2009-02-27 | 2016-02-02 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
WO2010099490A2 (en) | 2009-02-27 | 2010-09-02 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
US8641671B2 (en) | 2009-07-30 | 2014-02-04 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CA2777414C (en) * | 2009-10-13 | 2017-11-21 | Philip Morris Products S.A. | Air freshening device |
EP2319334A1 (en) † | 2009-10-27 | 2011-05-11 | Philip Morris Products S.A. | A smoking system having a liquid storage portion |
US8950394B2 (en) | 2010-01-12 | 2015-02-10 | Dance Biopharm Inc. | Preservative-free single dose inhaler systems |
US9545488B2 (en) | 2010-01-12 | 2017-01-17 | Dance Biopharm Inc. | Preservative-free single dose inhaler systems |
US20130269684A1 (en) | 2012-04-16 | 2013-10-17 | Dance Pharmaceuticals, Inc. | Methods and systems for supplying aerosolization devices with liquid medicaments |
AU2011227613B2 (en) | 2010-03-15 | 2015-09-03 | Virginia Commonwealth University | Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport |
WO2012106739A1 (de) | 2011-02-11 | 2012-08-16 | Helmut Buchberger | Inhalatorkomponente |
TWI546023B (zh) * | 2011-10-27 | 2016-08-21 | 菲利浦莫里斯製品股份有限公司 | 具有氣溶膠生產控制之電操作氣溶膠產生系統 |
US9854839B2 (en) | 2012-01-31 | 2018-01-02 | Altria Client Services Llc | Electronic vaping device and method |
JP6620016B2 (ja) | 2012-04-24 | 2019-12-11 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | ポータブル手持ち用圧力支援システム及び方法 |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
WO2014027267A2 (en) | 2012-08-13 | 2014-02-20 | Koninklijke Philips N.V. | Handheld dyspnea treatement device with drug and gas delivery |
WO2014046993A1 (en) * | 2012-09-24 | 2014-03-27 | Aerodesigns, Inc. | Flow diverter for a mouthpiece of a particule delivery device |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9603995B2 (en) | 2013-03-15 | 2017-03-28 | Tandem Diabetes Care. Inc. | Device and method for setting therapeutic parameters for an infusion device |
US10292424B2 (en) * | 2013-10-31 | 2019-05-21 | Rai Strategic Holdings, Inc. | Aerosol delivery device including a pressure-based aerosol delivery mechanism |
US10610651B2 (en) | 2014-06-09 | 2020-04-07 | Aerami Therapeutics, Inc. | Self-puncturing liquid drug cartridges and associated dispenser |
US10471222B2 (en) | 2014-07-01 | 2019-11-12 | Dance Biopharm Inc. | Aerosolization system with flow restrictor and feedback device |
US11273271B2 (en) | 2014-07-01 | 2022-03-15 | Aerami Therapeutics, Inc. | Aerosolization system with flow restrictor and feedback device |
US10857313B2 (en) | 2014-07-01 | 2020-12-08 | Aerami Therapeutics, Inc. | Liquid nebulization systems and methods |
US11051554B2 (en) | 2014-11-12 | 2021-07-06 | Rai Strategic Holdings, Inc. | MEMS-based sensor for an aerosol delivery device |
US10172388B2 (en) * | 2015-03-10 | 2019-01-08 | Rai Strategic Holdings, Inc. | Aerosol delivery device with microfluidic delivery component |
GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
GB201511358D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
GB201511359D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
WO2017178958A1 (en) * | 2016-04-10 | 2017-10-19 | Canabolabs | Device and a method for controlled administering of a therapeutic composition to a patient |
MX2018012922A (es) | 2016-04-27 | 2019-01-17 | Nicoventures Holdings Ltd | Sistema electronico de suministro de aerosol y vaporizador para el mismo. |
GB201617246D0 (en) * | 2016-10-11 | 2016-11-23 | British American Tobacco (Investments) Limited | Aerosol provision system and method |
FR3086845B1 (fr) | 2018-10-08 | 2023-01-20 | Juul Labs Inc | Elément de chauffage |
BR112021016694A2 (pt) * | 2019-03-15 | 2021-10-13 | Novo Nordisk A/S | Processo para secagem por pulverização de uma solução de alimentação, produto obtenível pelo processo, e, composição farmacêutica |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043695A2 (en) * | 2000-12-01 | 2002-06-06 | Batelle Memorial Institute | Stable, aerosolizable suspensions of proteins (e.g. insulin, dnase) in ethanol |
WO2002094342A2 (en) * | 2001-05-21 | 2002-11-28 | Vapotronics, Inc. | Compositions for protein delivery via the pulmonary route |
WO2003025527A2 (en) * | 2001-09-20 | 2003-03-27 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5915378A (en) * | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US6131567A (en) * | 1993-01-29 | 2000-10-17 | Aradigm Corporation | Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
US5970973A (en) * | 1993-01-29 | 1999-10-26 | Aradigm Corporation | Method of delivering insulin lispro |
US5672581A (en) * | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5743250A (en) * | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
JPH10501519A (ja) * | 1994-03-07 | 1998-02-10 | インヘイル・セラピューティック・システムズ | インシュリンを肺に送給できる方法および組成物 |
US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
AR002976A1 (es) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
DE19536902A1 (de) * | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
US6349719B2 (en) * | 1997-02-24 | 2002-02-26 | Aradigm Corporation | Formulation and devices for monitoring the efficacy of the delivery of aerosols |
EP1952802A3 (en) * | 1997-10-01 | 2009-06-17 | Novadel Pharma Inc. | Buccal, polar and non-polar spray or capsule |
EP1235606A1 (en) * | 1999-12-11 | 2002-09-04 | Glaxo Group Limited | Medicament dispenser |
US6540982B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
US6596261B1 (en) * | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
US6540983B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
US6585957B1 (en) * | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6447750B1 (en) * | 2000-05-01 | 2002-09-10 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6565833B1 (en) * | 2000-05-01 | 2003-05-20 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6548049B1 (en) * | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6464959B1 (en) * | 2000-05-01 | 2002-10-15 | Aeropharm Technology Incorporated | Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer |
US6468507B1 (en) * | 2000-05-01 | 2002-10-22 | Aeropharm Technology, Inc. | Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
US6669959B1 (en) * | 2000-07-18 | 2003-12-30 | Aeropharm Technology Incorporated | Modulated release particles for lung delivery |
US7077130B2 (en) * | 2000-12-22 | 2006-07-18 | Chrysalis Technologies Incorporated | Disposable inhaler system |
US6544497B2 (en) * | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6475468B2 (en) * | 2001-02-15 | 2002-11-05 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6551578B2 (en) * | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6485707B2 (en) * | 2001-02-15 | 2002-11-26 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6596262B2 (en) * | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
CA2357382A1 (en) * | 2001-09-17 | 2003-03-17 | Soma Networks, Inc. | Software update method, apparatus and system |
US6640050B2 (en) | 2001-09-21 | 2003-10-28 | Chrysalis Technologies Incorporated | Fluid vaporizing device having controlled temperature profile heater/capillary tube |
AU2003297087B2 (en) * | 2003-02-04 | 2009-06-11 | Philip Morris Products S.A. | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
WO2005037949A2 (en) * | 2003-10-07 | 2005-04-28 | Chrysalis Technologies Incorporated | Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine |
CA2564083C (en) * | 2004-04-23 | 2014-02-04 | Philip Morris Usa Inc. | Aerosol generators and methods for producing aerosols |
-
2004
- 2004-04-23 US US10/829,945 patent/US7683029B2/en active Active
- 2004-05-05 EP EP04751246.2A patent/EP1626746B1/en not_active Expired - Lifetime
- 2004-05-05 JP JP2006532550A patent/JP5054381B2/ja not_active Expired - Lifetime
- 2004-05-05 AU AU2004238235A patent/AU2004238235B2/en not_active Expired
- 2004-05-05 CA CA2524816A patent/CA2524816C/en not_active Expired - Lifetime
- 2004-05-05 WO PCT/US2004/013758 patent/WO2004100872A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043695A2 (en) * | 2000-12-01 | 2002-06-06 | Batelle Memorial Institute | Stable, aerosolizable suspensions of proteins (e.g. insulin, dnase) in ethanol |
WO2002043750A2 (en) * | 2000-12-01 | 2002-06-06 | Battelle Memorial Institute | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
WO2002094342A2 (en) * | 2001-05-21 | 2002-11-28 | Vapotronics, Inc. | Compositions for protein delivery via the pulmonary route |
WO2003025527A2 (en) * | 2001-09-20 | 2003-03-27 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180118701A (ko) * | 2016-03-24 | 2018-10-31 | 니코벤처스 홀딩스 리미티드 | 증기 제공 디바이스 |
JP2019512220A (ja) * | 2016-03-24 | 2019-05-16 | ニコベンチャーズ ホールディングス リミテッド | 蒸気供給デバイス |
KR102191356B1 (ko) | 2016-03-24 | 2020-12-15 | 니코벤처스 트레이딩 리미티드 | 증기 제공 디바이스 |
US11123501B2 (en) | 2016-03-24 | 2021-09-21 | Nicoventures Holdings Limited | Electronic vapor provision system |
US11213638B2 (en) | 2016-03-24 | 2022-01-04 | Nicoventures Trading Limited | Vapor provision system |
US11241043B2 (en) | 2016-03-24 | 2022-02-08 | Nicoventures Trading Limited | Vapor provision apparatus |
JP2018011932A (ja) * | 2016-07-18 | 2018-01-25 | アウトスタンディング ヘルスケア カンパニー リミテッド | ハンドヘルド噴霧器 |
Also Published As
Publication number | Publication date |
---|---|
WO2004100872A3 (en) | 2005-12-29 |
JP5054381B2 (ja) | 2012-10-24 |
US20040223917A1 (en) | 2004-11-11 |
AU2004238235B2 (en) | 2010-04-15 |
EP1626746B1 (en) | 2016-12-07 |
CA2524816C (en) | 2017-06-20 |
AU2004238235A1 (en) | 2004-11-25 |
US7683029B2 (en) | 2010-03-23 |
EP1626746A4 (en) | 2012-03-21 |
CA2524816A1 (en) | 2004-11-25 |
WO2004100872A2 (en) | 2004-11-25 |
EP1626746A2 (en) | 2006-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5054381B2 (ja) | インシュリンを含有する液体エアロゾル配合物及びエアロゾル生成装置及びエアロゾル化インシュリンを生成するための方法 | |
US7128067B2 (en) | Method and apparatus for generating an aerosol | |
JP4473126B2 (ja) | エアロゾル発生装置およびその使用方法 | |
ES2296312T3 (es) | Aerosol y un metodo y aparato para generar un aerosol. | |
JP4382483B2 (ja) | 制御された温度勾配の加熱部と毛細管とを有する液体蒸発装置 | |
US7458373B2 (en) | Aerosol generator for drug formulation | |
US7743766B2 (en) | Aerosol generating devices and methods for generating aerosols having controlled particle sizes | |
AU2001259804A1 (en) | Improved method and apparatus for generating an aerosol | |
JP2004516101A (ja) | 複数の加熱ゾーンを有するエアロゾル発生器とその使用方法 | |
JP2007534387A (ja) | エアゾール発生器及びエアゾール生成方法 | |
US20040223918A1 (en) | Aerosolization of cromolyn sodium using a capillary aerosol generator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120629 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120727 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5054381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150803 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |